July 19, 2007Journal of Interventional Cardiology
Single‐Center Randomized Evaluation of Paclitaxel‐Eluting Versus Conventional Stent in Acute Myocardial Infarction (SELECTION)
Why the study?
Does a paclitaxel-eluting stent reduce neointimal hyperplasia compared to a bare metal stent in patients with STEMI <12 hours undergoing primary PCI?
Population
80 consecutive patients with ST-elevation myocardial infarction <12 hours undergoing primary percutaneous…
Comparison
Paclitaxel-eluting stent (PES) vs Corresponding bare metal stent (BMS)
Design
RCT, Randomized
Follow-up
7 months
Authors
Discussion
Loading...
Member takes
Implication
PES may reduce NIH in STEMI primary PCI; leaves open whether it improves clinical outcomes versus BMS.
Structured PICO
Does a paclitaxel-eluting stent reduce neointimal hyperplasia compared to a bare metal stent in patients with STEMI <12 hours undergoing primary PCI?
P
Population
80 consecutive patients with ST-elevation myocardial infarction (STEMI) <12 hours undergoing primary percutaneous coronary intervention (PCI)
I
Intervention
Paclitaxel-eluting stent (PES)
C
Comparator
Corresponding bare metal stent (BMS)
O
Outcome
Percentage of the stent volume obstructed by neointimal proliferation (NIH) measured by intravascular ultrasound (IVUS) at a 7-month angiographic follow-upsurrogate
In patients with STEMI undergoing primary PCI, paclitaxel-eluting stents significantly reduced neointimal hyperplasia at 7 months compared to bare metal stents without increasing adverse clinical events.
Cite This Study
Chechi et al. (2007) studied this question.